Wang W, Teng Y, Xue J, Cai H, Pan Y, Ye X
Front Immunol. 2022; 13:846032.
PMID: 35464482
PMC: 9024121.
DOI: 10.3389/fimmu.2022.846032.
Chryssafidis P, Tsekouras A, Macheras P
Pharm Res. 2022; 39(4):691-701.
PMID: 35378697
DOI: 10.1007/s11095-022-03230-0.
Warren D, Haque S, McInerney M, Corbett K, Kastrati E, Ford L
Pharm Res. 2021; 38(9):1531-1547.
PMID: 34561814
DOI: 10.1007/s11095-021-03099-5.
Katev V, Tsibranska-Gyoreva S, Vinarov Z, Tcholakova S
Pharmaceutics. 2021; 13(8).
PMID: 34452248
PMC: 8399075.
DOI: 10.3390/pharmaceutics13081287.
Zhang R, Dong K, Wang Z, Miao R, Lu W, Wu X
Pharmaceutics. 2021; 13(8).
PMID: 34452222
PMC: 8399842.
DOI: 10.3390/pharmaceutics13081261.
Polypharmacy and Malnutrition Management of Elderly Perioperative Patients with Cancer: A Systematic Review.
Kose E, Wakabayashi H, Yasuno N
Nutrients. 2021; 13(6).
PMID: 34200493
PMC: 8227653.
DOI: 10.3390/nu13061961.
Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants.
Gackler A, Dolff S, Rohn H, Korth J, Wilde B, Eisenberger U
BMC Nephrol. 2019; 20(1):167.
PMID: 31088392
PMC: 6518767.
DOI: 10.1186/s12882-019-1340-z.
A Polyvinylpyrrolidone-Based Supersaturable Self-Emulsifying Drug Delivery System for Enhanced Dissolution of Cyclosporine A.
Lee D, Ho M, Choi Y, Kang M
Polymers (Basel). 2019; 9(4).
PMID: 30970802
PMC: 6432039.
DOI: 10.3390/polym9040124.
Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.
Tan A, Rao S, Prestidge C
Pharm Res. 2013; 30(12):2993-3017.
PMID: 23775443
DOI: 10.1007/s11095-013-1107-3.
Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.
Elgart A, Cherniakov I, Aldouby Y, Domb A, Hoffman A
Pharm Res. 2013; 30(12):3029-44.
PMID: 23686373
DOI: 10.1007/s11095-013-1063-y.
Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs.
Thomas N, Holm R, Garmer M, Karlsson J, Mullertz A, Rades T
AAPS J. 2012; 15(1):219-27.
PMID: 23180162
PMC: 3535117.
DOI: 10.1208/s12248-012-9433-7.
Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.
Ushijima K, Uemura O, Yamada T
Eur J Pediatr. 2011; 171(4):663-8.
PMID: 22116269
DOI: 10.1007/s00431-011-1633-0.
A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development.
Prajapati H, Dalrymple D, Serajuddin A
Pharm Res. 2011; 29(1):285-305.
PMID: 21861203
PMC: 3246583.
DOI: 10.1007/s11095-011-0541-3.
Clinical studies with oral lipid based formulations of poorly soluble compounds.
Fatouros D, Karpf D, Nielsen F, Mullertz A
Ther Clin Risk Manag. 2008; 3(4):591-604.
PMID: 18472981
PMC: 2374933.
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.
Custodio J, Wu C, Benet L
Adv Drug Deliv Rev. 2008; 60(6):717-33.
PMID: 18199522
PMC: 2292816.
DOI: 10.1016/j.addr.2007.08.043.
Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun.
Kees F, Bucher M, Schweda F, Gschaidmeier H, Faerber L, Seifert R
Naunyn Schmiedebergs Arch Pharmacol. 2007; 375(6):393-9.
PMID: 17571254
DOI: 10.1007/s00210-007-0169-3.
Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.
Kaukonen A, Boyd B, Charman W, Porter C
Pharm Res. 2004; 21(2):254-60.
PMID: 15032306
DOI: 10.1023/b:pham.0000016283.87709.a9.
Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.
Jiko M, Yano I, Wakasugi H, Saito H, Inui K
Pharm Res. 2002; 19(9):1362-7.
PMID: 12403074
DOI: 10.1023/a:1020363111398.
Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schadeli F, Marti H, Frey F, Uehlinger D
Clin Pharmacokinet. 2002; 41(1):59-69.
PMID: 11825097
DOI: 10.2165/00003088-200241010-00005.
Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
Dunn C, Wagstaff A, Perry C, Plosker G, Goa K
Drugs. 2001; 61(13):1957-2016.
PMID: 11708766
DOI: 10.2165/00003495-200161130-00006.